These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38443130)

  • 1. Early and Sustained Acne Lesion Reductions With Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel.
    Harper JC; Kircik LH; Gold M; Hebert AA; Sugarman JL; Green L; Gold LS; Baldwin H; Guenin E; DelRosso JQ
    J Drugs Dermatol; 2024 Mar; 23(3):125-131. PubMed ID: 38443130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis.
    Lain ET; Bhatia N; Kircik L; Gold LS; Harper JC; Bunick CG; Guenin E; Baldwin H; Feldman SR; Rosso JQD
    J Drugs Dermatol; 2024 Oct; 23(10):873-881. PubMed ID: 39361705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne in Adult and Pediatric Participants.
    Baldwin H; Gold LS; Harper JC; Alexis AF; Callender VD; Kircik L; Guenin E; Eichenfield LF
    J Drugs Dermatol; 2024 Jun; 23(6):394-402. PubMed ID: 38834226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug.
    Stein Gold L; Baldwin H; Kircik LH; Weiss JS; Pariser DM; Callender V; Lain E; Gold M; Beer K; Draelos Z; Sadick N; Pillai R; Bhatt V; Tanghetti EA
    Am J Clin Dermatol; 2022 Jan; 23(1):93-104. PubMed ID: 34674160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis.
    Kircik LH; Stein Gold L; Gold M; Weiss JS; Harper JC; Del Rosso JQ; Bunick CG; Bhatia N; Tanghetti EA; Eichenfield LF; Baldwin H; Draelos ZD; Callender VD; Han G; Gooderham MJ; Sadick N; Lupo MP; Lain ET; Werschler WP
    Dermatol Ther (Heidelb); 2024 May; 14(5):1211-1227. PubMed ID: 38724841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 study.
    Eichenfield LF; Stein Gold L; Kircik LH; Werschler WP; Beer K; Draelos ZD; Tanghetti EA; Papp KA; Baldwin H; Lain E; Sadick N; Gooderham MJ; Konda A
    Pediatr Dermatol; 2023; 40(3):452-459. PubMed ID: 36949579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adapalene 0.1%/benzoyl peroxide 2.5% gel: a review of its use in the treatment of acne vulgaris in patients aged ≥ 12 years.
    Keating GM
    Am J Clin Dermatol; 2011 Dec; 12(6):407-20. PubMed ID: 21967116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application Characteristics and Patient Preference of Triple-Combination vs Layered Topicals for Acne: Split-Face Study.
    Draelos ZD
    J Drugs Dermatol; 2024 Oct; 23(10):857-861. PubMed ID: 39361698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris.
    Cunliffe WJ; Holland KT; Bojar R; Levy SF
    Clin Ther; 2002 Jul; 24(7):1117-33. PubMed ID: 12182256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for moderate-to-severe acne: Efficacy and safety results from two randomized phase 3 trials.
    Stein Gold L; Lain E; Del Rosso JQ; Gold M; Draelos ZD; Eichenfield LF; Sadick N; Werschler WP; Gooderham MJ; Lupo M
    J Am Acad Dermatol; 2023 Nov; 89(5):927-935. PubMed ID: 37656094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatments for Moderate-to-Severe Acne Vulgaris: A Systematic Review and Network Meta-analysis.
    Harper JC; Baldwin H; Choudhury SP; Rai D; Ghosh B; Aman MS; Choudhury AR; Dutta SK; Dey D; Bhattacharyya S; Lin T; Joseph G; Dashputre AA; Tan JKL
    J Drugs Dermatol; 2024 Apr; 23(4):216-226. PubMed ID: 38564399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne.
    Gold LS; Tan J; Cruz-Santana A; Papp K; Poulin Y; Schlessinger J; Gidner J; Liu Y; Graeber M;
    Cutis; 2009 Aug; 84(2):110-6. PubMed ID: 19746769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study.
    Eichenfield LF; Alió Sáenz AB
    J Drugs Dermatol; 2011 Dec; 10(12):1382-96. PubMed ID: 22134562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3 %/Benzoyl Peroxide 2.5 % Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study.
    Stein Gold L; Weiss J; Rueda MJ; Liu H; Tanghetti E
    Am J Clin Dermatol; 2016 Jun; 17(3):293-303. PubMed ID: 26945741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adapalene/Benzoyl Peroxide Gel 0.3%/2.5%: A Safe and Effective Acne Therapy in All Skin Phototypes.
    Alexis AF; Cook-Bolden FE; York JP
    J Drugs Dermatol; 2017 Jun; 16(6):574-581. PubMed ID: 28686775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermal sensitization, safety, and tolerability of triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel from three clinical trials.
    Draelos ZD; Tanghetti EA; Kircik LH; Bhatia N; Zeichner JA; Sugarman JL; Stein Gold L
    J Dermatolog Treat; 2023 Dec; 34(1):2220446. PubMed ID: 37341243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of comedonal acne vulgaris with fixed-combination topical therapy.
    Gold MH; Baldwin H; Lin T
    J Cosmet Dermatol; 2018 Apr; 17(2):227-231. PubMed ID: 29380941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris.
    Langner A; Chu A; Goulden V; Ambroziak M
    Br J Dermatol; 2008 Jan; 158(1):122-9. PubMed ID: 18047518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed-dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: A multicenter, randomized, investigator-blind, parallel-group study.
    Hayashi N; Kurokawa I; Siakpere O; Endo A; Hatanaka T; Yamada M; Kawashima M
    J Dermatol; 2018 Aug; 45(8):951-962. PubMed ID: 29905384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Inflammatory Dose Doxycycline Plus Adapalene 0.3% and Benzoyl Peroxide 2.5% Gel for Severe Acne.
    Kircik LH
    J Drugs Dermatol; 2019 Sep; 18(9):924-927. PubMed ID: 31524349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.